Tysabri
Generic Name:
Natalizumab
Brand Names:
Tysabri
Tysabri Description:
Tysabri is an antibody used primarily in the treatment of multiple sclerosis (MS). Multiple sclerosis is a chronic condition characterized by damage to the protective myelin covering of nerve cells. This damage interferes with the proper communication of nerve signals between the brain and the body, resulting in decreased functionality and a wide variety of symptoms. Experts believe Tysabri works to inhibit the progression of the disease by binding to the white blood cells responsible for causing nerve damage and inhibiting their ability to cross the blood-brain barrier.
Tysabri Side Effects:
The most common side effects associated with Tysabri when used in the treatment of MS include:
- Depression
- Diarrhea
- Fatigue
- Headache
- Joint pain
- Respiratory tract infection
- Stomach pain
- Urinary tract infection
For more information, see our Tysabri side effects page.
Tysabri Uses:
Tysabri is used in the treatment of patients with relapsing MS. While it does not cure MS, Tysabri has been shown to slow the progression of the disease and reduce the likelihood that symptoms will worsen. Symptoms commonly associated with MS include reduced walking ability, vision problems, dizziness and decreased coordination.
Tysabri is also used in the treatment of moderate to severe Crohn’s disease in patients who have not responded to other medications. Crohn’s disease is a chronic condition characterized by inflammation of the bowels. Symptoms of the condition include abdominal pain, diarrhea and fever.
Tysabri Interactions:
Patients should talk to their doctor about the use of all medications, vitamins and supplements before beginning treatment with Tysabri. Because Tysabri affects the immune system, the following medications and other immunosuppressants should be avoided or used with caution:
- 6-mercaptopurine
- Azathioprine
- Corticosteroids
- Cyclosporine
- Methotrexate
- TNF inhibitors
Tysabri Dosage Information:
Typical Dosage Recommendations
Tysabri is administered in the form of an intravenous infusion by a health care professional. Patients receive an infusion once every four weeks. The infusion takes about an hour to complete and patients are generally required to stay an additional hour for monitoring. Over the course of the infusion, patients receive 300 mg of Tysabri.
Missing a Dose of Tysabri
Patients should schedule an appointment to receive an infusion of Tysabri once every four weeks. If a patient misses an appointment, they should call their health care professional to reschedule as soon as possible.
Tysabri Overdose
Because Tysabri is administered by a health care professional, the risk of accidental overdose is relatively low. However, if you have received an overdose of Tysabri, seek immediate medical attention.
Tysabri FDA Approval:
November 23, 2004
Tysabri Recall/Black Box Warning Information:
Tysabri carries a black box warning stating that patients using the medication are at an increased risk of developing progressive multifocal leukoencephalopathy (PML), a rare but potentially fatal viral infection in the brain. Patients with a weakened immune system are more susceptible to PML. Because of this risk, patients may only receive treatment with Tysabri through the TOUCH Prescribing Program and should only undergo treatment if alternative MS medications have been unsuccessful.
Other Warnings
Tysabri may increase the risk of liver complications. Contact your doctor or seek immediate medical attention if you experience dark urine, jaundice, nausea, fatigue or vomiting, as these may be signs of liver damage.
-
March 5, 2010, 9:38 am
-
March 4, 2010, 9:08 am
-
March 2, 2010, 5:46 pm
-
March 1, 2010, 1:00 pm
